8-K
Philip Morris International Inc. (PM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 19, 2025
Philip Morris International Inc.
(Exact name of registrant as specified in its charter)
| Virginia | 1-33708 | 13-3435103 | |
|---|---|---|---|
| (State or other jurisdiction<br><br>of incorporation) | (Commission File Number) | (I.R.S. Employer<br><br>Identification No.) | |
| 677 Washington Blvd, Ste. 1100 | Stamford | Connecticut | 06901 |
| --- | --- | --- | --- |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (203) 905-2410
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||
|---|---|---|---|---|---|---|
| Common Stock, no par value | PM | New York Stock Exchange | 2.750% Notes due 2026 | PM26A | New York Stock Exchange | |
| --- | --- | --- | ||||
| 2.875% Notes due 2026 | PM26 | New York Stock Exchange | ||||
| 0.125% Notes due 2026 | PM26B | New York Stock Exchange | ||||
| 3.125% Notes due 2027 | PM27 | New York Stock Exchange | ||||
| 3.125% Notes due 2028 | PM28 | New York Stock Exchange | ||||
| 2.875% Notes due 2029 | PM29 | New York Stock Exchange | ||||
| 3.375% Notes due 2029 | PM29A | New York Stock Exchange | ||||
| 2.750% Notes due 2029 | PM29D | New York Stock Exchange | ||||
| 3.750% Notes due 2031 | PM31B | New York Stock Exchange | ||||
| 0.800% Notes due 2031 | PM31 | New York Stock Exchange | ||||
| 3.250% Notes due 2032 | PM32 | New York Stock Exchange | ||||
| 3.125% Notes due 2033 | PM33 | New York Stock Exchange | ||||
| 2.000% Notes due 2036 | PM36 | New York Stock Exchange | ||||
| 1.875% Notes due 2037 | PM37A | New York Stock Exchange | ||||
| 6.375% Notes due 2038 | PM38 | New York Stock Exchange | ||||
| 1.450% Notes due 2039 | PM39 | New York Stock Exchange | ||||
| 4.375% Notes due 2041 | PM41 | New York Stock Exchange | ||||
| 4.500% Notes due 2042 | PM42 | New York Stock Exchange | ||||
| 3.875% Notes due 2042 | PM42A | New York Stock Exchange | ||||
| 4.125% Notes due 2043 | PM43 | New York Stock Exchange | ||||
| 4.875% Notes due 2043 | PM43A | New York Stock Exchange | ||||
| 4.250% Notes due 2044 | PM44 | New York Stock Exchange | ||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||||||
| --- | ||||||
| Emerging growth company | ☐ | |||||
| --- | --- | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | |||
| --- | --- | |||||
| Item 7.01. | Regulation FD Disclosure. | |||||
| --- | --- |
On September 19, 2025, Philip Morris International Inc. issued a press release announcing that its Board of Directors declared a regular quarterly dividend of $1.47 per common share, which press release is attached as Exhibit 99.1 to this Item 7.01 of this Current Report on Form 8-K and incorporated by reference herein.
In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in such filing or document.
| Item 9.01. | Financial Statements and Exhibits. |
|---|---|
| (d) | Exhibits. |
| --- | --- |
| 99.1 | Philip Morris International Inc. Press Release, dated September 19, 2025 (furnished pursuant to Item 7.01). |
| --- | --- |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document and contained in Exhibit 101) |
| --- | --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PHILIP MORRIS INTERNATIONAL INC. | |
|---|---|
| By: | /s/ DARLENE QUASHIE HENRY |
| Name: | Darlene Quashie Henry |
| Title: | Vice President, Associate General Counsel & Corporate Secretary |
Date: September 19, 2025
Document
| Exhibit 99.1 | |
|---|---|
| PRESS RELEASE |  |
| --- | --- |
| Investor Relations: | Media: David Fraser |
| Stamford, CT: +1 (203) 905 2413 | Lausanne: +41 582 424 500 |
| Lausanne: +41 582 424 666 | Email: David.Fraser@pmi.com |
| Email: InvestorRelations@pmi.com |
Philip Morris International Increases Dividend by 8.9% to Annualized Rate of $5.88 per Share
STAMFORD, CT, September 19, 2025 – The Board of Directors of Philip Morris International Inc. (PMI) (NYSE: PM) has increased the company’s regular quarterly dividend by 8.9% to an annualized rate of $5.88 per share.
The new quarterly dividend of $1.47 per share, up from $1.35 per share, is payable on October 20, 2025, to shareholders of record as of October 3, 2025. The ex-dividend date is October 3, 2025.
PMI has increased its annual dividend every year since becoming a public company in 2008, representing a total increase of 219.6%, or a compound annual growth rate of 7.1%.
For additional dividend information, see www.pmi.com/dividend.
Philip Morris International: A Global Smoke-Free Champion
Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. As of June 30, 2025, our smoke-free products were available for sale in 97 markets, and PMI estimates they were used by over 41 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 41% of PMI’s first-half 2025 total net revenues. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match’s General snus and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to “PMI”, “we”, “our” and “us” mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.
1